The Centers for Disease Control and Prevention’s most recent Antimicrobial Threats Report evaluates 19 drug-resistant bacteria and fungi, categorizing them by their danger to U.S. public health. The 2026 edition labels antimicrobial resistance an urgent public health threat, emphasizing its strain on healthcare systems, agricultural practices, and economic stability due to rising infection rates and treatment expenses.
Pathogens are classified using infection frequency, projected increases, transmission ease, and available treatment effectiveness. The Urgent Threats tier now features Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE), and drug-resistant gonorrhea. Each of these organisms poses severe health risks and leaves few viable treatment options.
Two organisms have moved into the Serious Threats category: drug-resistant Neisseria meningitidis, which demands immediate response, and drug-resistant dermatophytes, now placed on the Watch List for ongoing surveillance. The CDC has also broadened data collection for group A Streptococcus to encompass non-invasive infections, offering clearer insights into resistance patterns.
The report highlights that Clostridioides difficile (C. diff) infections have decreased sufficiently to reclassify its threat level from Urgent to Serious. Despite this improvement, it remains a primary cause of hospital-acquired infections and a significant contributor to healthcare costs. The CDC emphasizes that strict infection control measures and judicious antibiotic use are essential to preventing a resurgence.
Improvements in data tracking now provide a more accurate picture of resistance trends. For instance, extended-spectrum cephalosporin-resistant Enterobacterales now includes additional pathogens such as Klebsiella aerogenes. Monitoring for C. diff has also expanded to cover both hospital and community-acquired cases, revealing a more complete spread of the bacterium.